Drug Information

Drug General Information
Drug ID
D0R1JV
Former ID
DAP000079
Drug Name
Ziprasidone
Synonyms
Geodon; Zeldox; Zipradon; Ziprasidona; Ziprasidonum; Ziprazidone; Ziprasidone hydrochloride; Ziprasidone mesylate trihydrate; CP 88059; CP 88059-01; Geodon (TN); Zeldox (TN); Zipradon (TN); Ziprasidone (INN); Ziprasidone [INN:BAN]; CP-88,059; CP-88059-1; CP-88,059-01; CP-88,059-1; 5-[2-[4-(1,2-benzothiazol-3-yl)piperazin-1-yl]ethyl]-6-chloro-1,3-dihydroindol-2-one; 5-{2-[4-(1,2-benzisothiazol-3-yl)piperazin-1-yl]ethyl}-6-chloro-1,3-dihydro-2H-indol-2-one; 5-{2-[4-(1,2-benzothiazol-3-yl)piperazin-1-yl]ethyl}-6-chloro-1,3-dihydro-2H-indol-2-one; 6-chloro-5-[2-[4-(7-thia-8-azabicyclo[4.3.0]nona-1,3,5,8-tetraen-9-yl)piperazin-1-yl]ethyl]-1,3-dihydroindol-2-one
Drug Type
Small molecular drug
Indication Schizophrenia [ICD9: 295; ICD10:F20] Approved [536526], [541192]
Therapeutic Class
Antipsychotic Agents
Company
Pfizer
Structure
Download
2D MOL

3D MOL
Formula
C21H21ClN4OS
InChI
InChI=1S/C21H21ClN4OS/c22-17-13-18-15(12-20(27)23-18)11-14(17)5-6-25-7-9-26(10-8-25)21-16-3-1-2-4-19(16)28-24-21/h1-4,11,13H,5-10,12H2,(H,23,27)
InChIKey
MVWVFYHBGMAFLY-UHFFFAOYSA-N
CAS Number
CAS 146939-27-7
PubChem Compound ID
60854
PubChem Substance ID
9771, 7481431, 7980909, 8187099, 14782044, 26719835, 43118192, 46386625, 46507627, 48416712, 49830895, 49984774, 56352942, 57314152, 80112580, 81065539, 85175463, 85209383, 93166200, 96025370, 103194712, 103979184, 104321820, 119525882, 125341301, 126496584, 126618135, 126648879, 126671672, 127275844, 127275845, 127275846, 127275847, 127275848, 127275849, 127275850, 127275851, 127275852, 128655450, 131299396, 134337407, 134338706, 135026475, 135651359, 137001426, 142394815, 144205747, 144207074, 144224623, 152039802
ChEBI ID
ChEBI:10119
SuperDrug ATC ID
N05AE04
SuperDrug CAS ID
cas=146939277
Target and Pathway
Target(s) D(2) dopamine receptor Target Info Agonist [536935]
KEGG Pathway Rap1 signaling pathway
cAMP signaling pathway
Neuroactive ligand-receptor interaction
Gap junction
Dopaminergic synapse
Parkinson's disease
Cocaine addiction
Alcoholism
PANTHER Pathway Heterotrimeric G-protein signaling pathway-Gi alpha and Gs alpha mediated pathway
Heterotrimeric G-protein signaling pathway-Gq alpha and Go alpha mediated pathway
Dopamine receptor mediated signaling pathway
Nicotine pharmacodynamics pathway
Reactome Dopamine receptors
G alpha (i) signalling events
WikiPathways Hypothetical Network for Drug Addiction
Monoamine GPCRs
GPCRs, Class A Rhodopsin-like
Genes and (Common) Pathways Underlying Drug Addiction
GPCR ligand binding
GPCR downstream signaling
Nicotine Activity on Dopaminergic Neurons
References
Ref 536526Emerging anxiolytics. Expert Opin Emerg Drugs. 2007 Nov;12(4):541-54.
Ref 541192(http://www.guidetopharmacology.org/) Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 59).
Ref 536935Striatal and extrastriatal D2/D3-receptor-binding properties of ziprasidone: a positron emission tomography study with [18F]Fallypride and [11C]raclopride (D2/D3-receptor occupancy of ziprasidone). JClin Psychopharmacol. 2008 Dec;28(6):608-17.

If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.